Metallonitrosyl complexes are promising as nitric oxide (NO) donors for the treatment of cardiovascular, endothelial, and pathogenic diseases, as well as cancer. Recently, the reduced form of NO– (protonated as HNO, nitroxyl, azanone, isoelectronic with O2) has also emerged as a candidate for therapeutic applications including treatment of acute heart failure and alcoholism. Here, we show that HNO is a product of the reaction of the RuII complex [Ru(bpy)2(SO3)(NO)]+ (1) with glutathione or N-acetyl-L-cysteine, using met-myoglobin and carboxy-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide) as trapping agents. Characteristic absorption spectroscopic profiles for HNO reactions with met-myoglobin were obtained, as well as EPR evidence from carboxy-PTIO experiments. Importantly, the product HNO counteracted NO-induced as well as hypoxia-induced stabilization of the tumor-suppressor HIF-1α in cancer cells. The functional disruption of neovascularization by HNO produced by this metallonitrosyl complex was demonstrated in an in vitro angiogenesis model. This behavior is consistent with HNO biochemistry and contrasts with NO-mediated stabilization of HIF-1α. Together, these results demonstrate for the first time thiol-dependent production of HNO by a ruthenium complex and subsequent destabilization of HIF-1α. This work suggests that the complex warrants further investigation as a promising antiangiogenesis agent for the treatment of cancer.
Monosodium urate crystals (MSU) deposition induces articular inflammation known as gout. This disease is characterized by intense articular inflammation and pain by mechanisms involving the activation of the transcription factor NFκB and inflammasome resulting in the production of cytokines and oxidative stress. Despite evidence that MSU induces iNOS expression, there is no evidence on the effect of nitric oxide (NO) donors in gout. Thus, the present study evaluated the effect of the ruthenium complex donor of NO {[Ru(bpy)2(NO)SO3](PF6)} (complex I) in gout arthritis. Complex I inhibited in a dose-dependent manner MSU-induced hypersensitivity to mechanical stimulation, edema and leukocyte recruitment. These effects were corroborated by a decrease of histological inflammation score and recruitment of Lysm-eGFP+ cells. Mechanistically, complex I inhibited MSU-induced mechanical hypersensitivity and joint edema by triggering the cGMP/PKG/ATP-sensitive K (+) channels signaling pathway. Complex I inhibited MSU-induced oxidative stress and pro-inflammatory cytokine production in the knee joint. These data were supported by the observation that complex I inhibited MSU-induced NFκB activation, and IL-1β expression and production. Complex I also inhibited MSU-induced activation of pro-IL-1β processing. Concluding, the present data, to our knowledge, is the first evidence that a NO donating ruthenium complex inhibits MSU-induced articular inflammation and pain. Further, complex I targets the main physiopathological mechanisms of gout arthritis. Therefore, it is envisaged that complex I and other NO donors have therapeutic potential that deserves further investigation.
The development of new medical therapies has greatly advanced, and phototherapy has shown major potential. Ruthenium complexes have showed promising phototherapeutical applications, particularly against cancer. Despite that, cell selectivity and uptake seem to be one bottleneck issue for those compounds. Biotin has been used as an anchor to provide drug selectivity to certain cancer cells, which overexpressed biotin receptors. This approach was taken here to modify a previously reported anthracene- and dppz-based ruthenium(II) compound (Ru-anth), which exhibited strong DNA binding and high singlet oxygen photoproduction. This new biotinylated compound (Ru-biot) was characterized and its chemical, biochemical and biological properties investigated. Indeed, the biotin linker did not significantly alter the DNA binding affinity (Kb = 6 × 106) of this compound, neither its singlet oxygen photoproduction (blue light, ΦΔ = 0.75), allowing further investigations. Notably, this new compound showed also great 1O2 production with green (ΦΔ = 0.51) and red (ΦΔ = 0.19) light. Biological studies showed antimicrobial activity against S. aureus with MIC of 14 μmol L−1. Interestingly, neither the non-biotinylated nor the biotinylated ruthenium compounds showed any cytotoxicity against human cancer or healthy cell lines in the dark. However, upon light irradiation, we observed very selective cytotoxicity only of the biotinylated compound against only A549 and MCF7 cancer cells, well-known to overexpress biotin receptors. Altogether, these results showed that a suitable combination of ligands and proper selection of handles can provide a ruthenium compound with multiple essential functionalities, such as selectivity (cancer), biological target specificity (DNA) and enhanced controllable generation of toxic cargos (1O2), making a promising agent for phototherapy.
Parasites of the genusLeishmaniaare capable of inhibiting effector functions of macrophages. These parasites have developed the adaptive ability to escape host defenses; for example, they inactivate the NF-κB complex and suppress iNOS expression in infected macrophages, which are responsible for the production of the major antileishmanial substance nitric oxide (NO), favoring then its replication and successful infection. Metal complexes with NO have been studied as potential compounds for the treatment of certain tropical diseases, such as ruthenium compounds, known to be exogenous NO donors. In the present work, the compoundcis-[Ru(bpy)2SO3(NO)]PF6, or RuNO, showed leishmanicidal activity directly and indirectly on promastigote forms ofLeishmania (Leishmania) amazonensis. In addition, treatment with RuNO increased NO production by reversing the depletion of NO caused byLeishmania. We also found increased expression of Akt, iNOS, and NF-κB in infected and treated macrophages. These results demonstrated that RuNO was able to kill the parasite by NO release and modulate the transcriptional capacity of the cell.